Introduction {#s1}
============

Acute respiratory tract infection (RTI) is a frequent illness, generally of viral origin. Clinical conditions range from mild cold symptoms to influenza, the most serious form of common acute RTI. In most health care settings, diagnostic tests that would differentiate between influenza and other forms of viral RTIs are not routinely performed. Although most acute RTI episodes resolve spontaneously ([@B14]), RTIs result in a high number of outpatient consultations and pose a heavy burden on society and health care systems. Strategies to reduce the incidence and effects of common acute RTIs attract major public health interest, given the large number of individuals affected each year as well as the impact on patient health outcomes and on medical and personal costs. In order to facilitate disease monitoring, this overlapping group of acute viral respiratory infections is generally referred to as influenza-like illness (ILI) ([@B19]). Recently, the WHO defined ILI as "an acute respiratory illness with a measured temperature of \>38°C and cough, with \[symptom\] onset within the past 10 days" ([@B18]). In the USA, information on outpatient visits to health care providers for ILI is collected through the US Outpatient Influenza-like Illness Surveillance Network ([@B7]). For this system, ILI is defined as having a fever (\>100°F or \>37.8°C) and cough and/or sore throat (in the absence of a known cause).

Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit on the host ([@B24]). Interest in the potential impact of probiotics on health outcomes has been increasing in recent years. This impact has been investigated in several therapeutic areas, including RTIs. According to a recent survey among health care providers who routinely prescribe medication, 61% had recommended probiotic food or supplements to their patients ([@B17]). Several clinical studies have evaluated the effectiveness of probiotics when administered to healthy subjects in reducing the incidence and duration of infectious respiratory conditions ([@B15]; [@B34]; [@B2]). Two large meta-analyses have investigated the preventative effect of taking probiotics versus placebo. The York Health Economics Consortium (YHEC) performed a systematic review and meta-analysis on the duration of illness in healthy children and adults who developed acute respiratory infectious conditions ([@B28]); results showed that probiotics significantly reduced RTI episode duration. The Cochrane Collaboration assessed the effectiveness of probiotics, compared with placebo, in the prevention of acute upper RTIs in healthy people of all ages and reported that probiotics reduced RTI incidence and antibiotic prescription rate ([@B20]).

Objectives {#s2}
==========

Based on the above-mentioned meta-analyses reporting the positive outcomes of probiotics in RTI, we hypothesized that generalized use of probiotics would meaningfully reduce RTI duration and/or frequency and thus the use of health care resources and related expenses for RTI in the USA. The objective of this study was to quantify the effect of probiotics on RTI-related health and cost outcomes in the US primary care setting. The analysis also explored the effect of probiotic intake on productivity loss.

Methods {#s3}
=======

Model Description {#s3_1}
-----------------

Our economic analysis compared generalized probiotic intake versus no probiotic intake. We used a state-transition microsimulation model, which enabled us to track the disease pathway of each subject, accumulating costs and events dependent on individual baseline and/or time-varying characteristics. Two previously published economic evaluations of probiotics in RTIs inspired the model structure ([@B32]; [@B33]). The study cohort was a representative sample of the US population in terms of demographics and known RTI-related risk factors. Model convergence was tested in order to ensure that the number of individuals in the analysis was sufficient to obtain robust results. The model comprised two health states, "at risk" and "ongoing RTI" ([**Figure 1**](#f1){ref-type="fig"}).

![Model structure.](fphar-10-00980-g001){#f1}

All individuals in the cohort were evaluated under each of the two probiotic intake regimens, generalized probiotic use versus no probiotic use. For the analysis of each regimen, each subject started in the "at-risk" state and could move to "ongoing RTI" according to predefined transition probabilities, calculated based on US epidemiology data. The cycle length was 1 day, and the time horizon was 1 year, reflecting the 2017--2018 influenza season of FluView data from the Centers for Disease Control and Prevention (CDC).

Model Inputs and Data Sources {#s3_2}
-----------------------------

### Probiotic Effect {#s3_2_1}

The clinical effects of probiotics were obtained from the meta-analyses published by the YHEC ([@B28]) and Cochrane ([@B20]). These were used to conduct two independent scenario analyses comparing generalized probiotic use versus non-use, each based on different assumptions: YHEC showed a significantly shorter duration of −0.77 days \[−1.50 to −0.04\] on an average duration of 7.4 days per episode of RTI, among otherwise healthy children and adults taking probiotics compared to those taking placebo. The Cochrane study reported that probiotics significantly reduced RTI duration by 1.89 days \[1.75 to 2.03\] per episode of an average duration of 8.82 days and RTI incidence by 30% (RR = 0.70 \[0.50 to 0.84\]) ([**Table 1**](#T1){ref-type="table"}). The authors also found a significant reduction of the antibiotic prescription rate of 35% (RR = 0.65 \[0.45 to 0.94\]), which was applied to both scenarios. Additionally, the YHEC meta-analysis studied the impact of probiotics on work absenteeism. The reported standardized mean difference (SMD) in the number of days absent from work was used to estimate the impact of probiotics on productivity loss. The Cochrane meta-analysis focused on unvaccinated individuals; therefore, no impact of probiotics sourced from the Cochrane meta-analysis was applied in vaccinated patients.

The clinical effects of probiotics were obtained from the meta-analyses published by the YHEC ([@B28]) and Cochrane ([@B20]). These were used to conduct two independent scenario analyses comparing generalized probiotic use versus non-use, each based on different assumptions: YHEC showed a significantly shorter duration of −0.77 days \[−1.50 to −0.04\] on an average duration of 7.4 days per episode of RTI, among otherwise healthy children and adults taking probiotics compared to those taking placebo. The Cochrane study reported that probiotics significantly reduced RTI duration by 1.89 days \[1.75 to 2.03\] per episode of an average duration of 8.82 days and RTI incidence of 0.70 \[0.50 to 0.84\] ([**Table 1**](#T1){ref-type="table"}). The authors also found a significant reduction of the antibiotic prescription rate of 0.65 \[0.45 to 0.94\], which was applied to both scenarios. Additionally, the YHEC meta-analysis studied the impact of probiotics on work absenteeism. The reported standardized mean difference (SMD) in the number of days absent from work was used to estimate the impact of probiotics on productivity loss. The Cochrane meta-analysis focused on unvaccinated individuals; therefore, no impact of probiotics sourced from the Cochrane meta-analysis was applied in vaccinated patients.

###### 

Summary of model inputs---epidemiological and resource utilization parameters.

  Model parameters                                                                                                                                                                              Reference                                                                               
  ------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------- ------------------------------------------------ -------------------------
  Influenza vaccination coverage                                                                                                                                                                [@B5]                                                                                   
  **Steps to ILI incidence estimation**                                                                                                                                                                                                                                                 
  All cause consultations, all ages                                                                                                                                                             NAMCS                                                                                   
  Total ILI consultations, all ages                                                                                                                                                             [@B6]                                                                                   
  **Clinical effect of probiotics**                                                                                                                                                                                                                                                     
  YHEC                                       On RTI incidence: NA/On RTI duration: --0.77 days vs placebo/On antibiotic use: NA/On work absenteeism: --0.17 SMD                                 [@B28]                                                                                  
  Cochrane                                   On RTI incidence: RR = 0.70\* vs placebo/On RTI duration: --1.89 days vs placebo/On antibiotic use: RR = 0.65 vs placebo/On work absenteeism: NA   [@B20]                                                                                  
  **Risk factors**                                                                                                                                                                                                                                                                      
  *Smoking*                                                                                                                                                                                                                                                                             
  Active smokers                                                                                                                                                                                [@B8], [@B9]                                                                            
  Passive smokers                                                                                                                                                                               [@B38]                                                                                  
  *Shared indoor environment*                                                                                                                                                                                                                                                           
  School enrollment                                                                                                                                                                             [@B44]                                                                                  
  Employment status                                                                                                                                                                             [@B4]                                                                                   
  Living in a nursing home                                                                                                                                                                      [@B23]                                                                                  
  **Impact of risk factors on RTI**                                                                                                                                                                                                                                                     
  *Smoking*                                                                                                                                                                                                                                                                             
  Active smokers                             On RTI incidence: NA/On RTI duration: +16.8% vs no smokers                                                                                         [@B1]                                                                                   
  Passive smokers                            On RTI incidence: RR = 1.15/On RTI duration: +4.5% vs no smokers                                                                                   [@B1]                                                                                   
  *Shared indoor environment*                                                                                                                                                                                                                                                           
  Day care (including school) vs home care   On RTI incidence: RR = 1.22/On RTI incidence: NA                                                                                                   [@B36]                                                                                  
  Shared office vs alone                     On RTI incidence: RR = 1.07/On RTI incidence: NA                                                                                                   [@B25]                                                                                  
  **Cost parameters**                                                                                                                                                                                                                                                                   
  *Direct cost parameters*                   **% using the resource**                                                                                                                           **Unit cost (by payer) (USD)**         **Copayment (USD)**                              
  PCP cost^\#^                               100%                                                                                                                                               74.16\*\*                              25\*\*                                           Physician Fee Schedule
  Antibiotics (amoxicillin)^§^               29%                                                                                                                                                6.49                                   0                                                Medi-Span Price Rx 2018
  Non-antibiotic medication                  56.62%                                                                                                                                             26.59                                  11                                               [@B27]
  *Indirect cost parameters*                 **% missed days**                                                                                                                                  **Number of missed days, mean (SD)**   **Cost per day lost (employer) (USD)** **^†^**   
  Employee with ILI                          42%                                                                                                                                                1.7 (5.1)                              217.92                                           [@B40], [@B4]
  Sick children with ILI                     18%                                                                                                                                                0.5 (1.5)                              217.92                                           [@B40], [@B4]

SMD, standardized mean difference; NA, not applicable; CDC, Centers for Disease Control and Prevention; ILI, influenza-like illness; NAMCS, National Ambulatory Medical Care Survey; YHEC, York Health Economics Consortium; RTI, respiratory tract infection; RR, risk ratio; MMWR, Morbidity and Mortality Weekly Report; PCP, primary care physician.

\*Transformed from OR to RR using exact numbers and sample size.

\*\*Reimbursed unit price of current procedural terminology code 99213.

^\#^Published by the Centers for Medicare & Medicaid Services.

^§^Commonly used and recommended for by the CDC.

^†^Cost per absent day is based on daily wage from (Bureau of Labor Statistics, 2018).

### Demographic Structure of the Study Population {#s3_2_2}

The demographic data by age and gender were obtained from the [@B44].

### Respiratory Tract Infection Incidence and Vaccination Status {#s3_2_3}

The daily RTI incidence probabilities were estimated based on the ILI outpatient consultation rate as reported by [@B6]. The vaccination status of American citizens was taken into account in the base case to allow exclusion of a probiotic effect in vaccinated patients, as the Cochrane scenario excluded vaccinated subjects. That is, for a vaccinated patient, we specified that RTI incidence and duration were identical between the probiotic and no-probiotic scenarios, effectively excluding probiotic effects for vaccinated patients. The prevalence of influenza vaccination in the USA was obtained from the [@B5]. The lower probability of getting ILI for vaccinated subjects was estimated based on the vaccination effect reported by two meta-analyses, [@B26] and [@B16] for children and adults, respectively.

### Risk Factors {#s3_2_4}

Several risk factors other than age are known to have an impact on RTI, such as smoking or a daily shared indoor environment. To guarantee stable and robust results, these risk factors were not part of the base case but were included in subgroup analyses that assessed the variability of the results across different subpopulations and identified subpopulations likely to benefit more from the use of probiotics.

[@B1] carried out a randomized controlled trial (RCT) among 39,876 female participants to assess active and passive smoking in relation to frequency of colds. The study showed no significant impact of active smoking on upper RTI incidence, while it significantly increased the risk of having a longer duration (RR \> 7 days) of 1.62 \[1.40 to 1.87\] for light smokers and 2.63 \[2.02 to 3.44\] for heavy smokers. In passive smokers, a higher RTI incidence \[1.15 (1.05 to 1.26)\] and a longer RTI duration per episode \[4.5 (0.1 to 8.9)\] were observed in comparison to non-smokers.

The CDC Morbidity and Mortality Weekly Report (MMWR) published the prevalence of active smoking among adults ([@B8]) as well as among middle and high school students ([@B9]). The prevalence of passive smoking was obtained from the [@B38].

Daily shared indoor environments (i.e. children studying in school and adults working in a shared office) have been shown to increase the risk of acquiring an RTI, with an associated impact on RTI incidence ([@B14]). Children in day care centers, aged 1--7 years, appeared to have a significantly higher risk of getting a respiratory infection than children staying at home \[1.22 (1.13 to 1.31)\] ([@B36]). In the model, this effect was also applied for children aged 8--15 years. The results of a study on adults working in a shared office environment showed a higher risk of having more than two cold episodes during a 12-month period \[1.64 (1.08 to 2.50)\] ([@B25]). Prevalence of shared indoor environments was based on school enrollment ([@B43]), employment status ([@B4]), and proportion of people living in a nursing home ([@B23]).

### Respiratory Tract Infection-Related Costs {#s3_2_5}

Resource utilization consisted of estimated consultation fees for a primary care physician (PCP), cost of antibiotics and other prescribed medication resource use, and copayment ([@B22]). Inpatient costs were not considered. Cost for consulting a PCP was taken from the Physician Fee Schedule ([@B11]) and based on the assumption of a single PCP consultation per RTI episode to align with the estimates of the RTI incidence derived from the number of ILI outpatient visits, collected through the US Outpatient Influenza-like Illness Surveillance Network ([@B7]). The cost of antibiotics was based on a recent study that reported an antibiotic prescription during influenza seasons of 29% ([@B21]). Due to the lack of data availability, prescribed medications other than antibiotics were included in this analysis as a single cost item, based on a publication that assessed health care costs associated with influenza ([@B27]). The cost of over-the-counter medication among the general population was not included, as reliable information on cost estimates was insufficient.

A broader societal perspective was taken by combining the cost covered by insurance/copayment and ILI-related productivity losses ([@B40]). An overview of all data inputs and sources is presented in [**Table 1**](#T1){ref-type="table"}.

### Statistical Analyses {#s3_2_6}

The model was used to quantify the impact of generalized probiotic use versus no probiotic use on each of the following outcomes: number of ILI events, number of ILI days, number of antibiotic prescriptions, number of days missed from work, PCP visit costs, medication costs, and productivity loss. Subgroup analyses were conducted on age, vaccination status, smoking status (active and passive), and living or working in a shared indoor environment. Two additional scenario analyses were conducted: (1) comparing a population with generalized probiotic intake versus a population with current probiotic intake in the USA and (2) considering an alternative data source for productivity loss in ILI patients.

Uncertainty around model results due to model assumptions was further explored in a one-way sensitivity analysis, which considered two key parameters: avoided RTI days and saved total societal cost with probiotic use versus no probiotic use ([**Table 2**](#T2){ref-type="table"}). All statistical analyses were performed and produced in Microsoft Excel (2016), and the model was developed with the utilization of Visual Basic for Applications (VBA) in Excel.

###### 

Sensitivity analyses: lower and upper bounds of variation for model parameters.

  Parameter                                     Value    Source            
  --------------------------------------------- -------- -------- -------- -----------------------------------------------
  **YHEC scenario (probiotic effects)**                                    
  Change duration per RTI episode               0.77     0.04     1.5      95% CI, [@B28]
  Reduced antibiotic prescription (RR)\*        0.65     0.45     0.94     95% CI, [@B20]
  Change in loss of productivity, adults        0.87     0.153    1.581    95% CI, [@B28] + assumption
  Change in loss of productivity, children^‡^   0.26     0.045    0.465    
  **Cochrane scenario (probiotic effects)**                                
  Change in duration per RTI\* episode          1.89     1.75     2.03     95% CI, [@B20]
  Reduced incidence of RTI\* (RR)               0.70     0.5      0.84     
  Reduced antibiotic prescription\* (RR)        0.65     0.45     0.94     
  Change in loss of productivity, adults        0.87     0.153    1.581    95% CI, [@B28] + assumption
  Change in loss of productivity, children^‡^   0.26     0.045    0.465    
  **Both scenarios**                                                       
  Probability of non-antibiotic medication      56.62%   50.00%   60.00%   Assumption based on expert opinion
  Antibiotic cost, 0--14 years                  2.95     1.48     4.43     ±50% of base case value
  Antibiotic cost, 15+ years                    3.54     1.77     5.31     
  PCP cost                                      99.16    69.64    124.44   Codes 99212 and 99214, Physician Fee Schedule

Upper and lower limits represent 95% confidence interval as reported by the indicated source. PCP, primary care physician; RR, risk ratio; RTI, respiratory tract infection; YHEC, York Health Economics Consortium; PCP, primary care physician.

\*Applied in non-vaccinated individuals only.

^‡^Productivity loss caused by sick child.

Model Validity {#s3_3}
--------------

A cohort of 329,256 individuals was generated based on the chosen sample rate. The model demonstrated a high precision in simulating the US population structure by age and gender ([**Figure 2**](#f2){ref-type="fig"}). High accuracy was also achieved in simulating risk factor prevalence as well as ILI event incidence with \<0.2% difference in total number of RTI events when compared to the FluView data.

![Population structure by age and gender in the model cohort versus USA population.](fphar-10-00980-g002){#f2}

To ensure that the model provides robust results with a chosen sample size, convergence testing was conducted and confirmed the stability of estimates for both the YHEC and the Cochrane scenarios.

Results {#s4}
=======

In the YHEC scenario, the base case analysis showed that the shorter duration of disease associated with probiotic intake engendered 19,012 fewer acute RTI days compared to no probiotics, while 1,393 antibiotic courses (−19.4%) were avoided in the evaluated study cohort ([**Table 3**](#T3){ref-type="table"}). As the YHEC meta-analysis did not investigate the effect of probiotics on RTI incidence, the difference in the number of RTI episodes and related physician consultations was not part of the base case analysis. When these outcomes are projected to the actual US population, this translates to potential cost savings associated with probiotic use of 4.6 million USD for the health care payer. When productivity loss related to absence from work is included, probiotic intake has the potential for additional total cost savings of 784 million USD for the USA.

###### 

York Health Economics Consortium (YHEC) scenario: impact of probiotics on RTI-related events versus no probiotics (sample size 1/1,000).

  Event outcome               Probiotics   No probiotics   Difference   Difference in %
  --------------------------- ------------ --------------- ------------ -----------------
  RTI days                    163,701      182,713         −19,012      −10.41%
  No. of antibiotic courses   5,804        7,197           −1,393       −19.36%
  No. of missed work days     3,397        6,973           −3,576       −51.29%

RTI, respiratory tract infection.

In the Cochrane scenario, the base case analysis of the effect of probiotics on both a reduced RTI incidence and a shorter disease duration demonstrated a decrease of 4,103 RTI episodes, a reduction of 54,491 RTI days, and 2,166 antibiotics courses averted in the probiotic arm compared to the arm without probiotics ([**Table 4**](#T4){ref-type="table"}). Projection of the base case outcomes to the US population showed that probiotic use would result in cost savings of 373 million USD for the health care payer. For this scenario, when generalized probiotic use versus no probiotic use are compared, the total decrease in RTI-associated expenses due to medical resource utilization and productivity loss combined equaled 1.4 billion USD.

###### 

Cochrane scenario: impact of probiotics on RTI-related events versus no probiotics (sample size 1/1,000).

  Event outcome               Probiotics   No probiotics   Difference   Difference in %
  --------------------------- ------------ --------------- ------------ -----------------
  RTI episodes                20,568       24,671          −4,103       −16.63%
  RTI days                    163,107      217,598         −54,491      −25.04%
  No. of antibiotic courses   5,026        7,192           −2,166       −30.12%
  No. of missed work days     2,753        6,971           −4,217       −60.50%

RTI, respiratory tract infection.

Subgroup analyses of risk factors showed that an incremental benefit of probiotics was observed in children aged ≤15 years, in individuals sharing a daily indoor environment, and in passive smokers. The positive impact of probiotics was highest in the pediatric population that constituted 19.8% of the cohort population, but in which probiotic use contributed to 41.3% of avoided RTI days and 26.3% of the total cost savings. Results of the unvaccinated subgroup analysis showed that the 53.7% of unvaccinated individuals in the model population contributed to 56% of avoided RTI days and 63.9% of saved total costs. The outcomes of the subgroup analyses are summarized in [**Table 5**](#T5){ref-type="table"}.

###### 

Subgroup analysis by risk factors (age, smoking, and living in a shared daily environment) (sample size 1/1,000).

  Subgroup                                      \% of model population   \% of avoided RTI days   \% of total societal cost savings
  --------------------------------------------- ------------------------ ------------------------ -----------------------------------
  Children (aged 0--15)                         19.81%                   41.30%                   26.29%\*
  Passive smokers                               26.59%                   34.60%                   30.03%
  Individuals with shared indoor environments   53.19%                   55.55%                   71.88%
  Unvaccinated individuals                      53.70%                   56.10%                   63.87%
  **Cochrane scenario**                                                                           
  Children (aged 0--15)                         19.81%                   34.35%                   34.62%\*
  Active smokers                                12.50%                   11.93%                   13.13%
  Passive smokers                               26.59%                   34.11%                   31.23%
  Individuals with shared indoor environments   53.19%                   58.25%                   67.24%

RTI, respiratory tract infection; YHEC, York Health Economics Consortium.

\*Excluding productivity loss.

In the base case analysis, current probiotic intake was disregarded even though probiotic consumption would be expected to influence the reported RTI incidences and subsequently our study outcomes. Therefore, a scenario analysis was carried out based on estimated probiotic intake. According to the National Health Interview Survey (NHIS), 1.6% of American adults take probiotics and/or prebiotics as dietary supplements ([@B13]). Further, it has been estimated that dietary supplements account for about 36% of the probiotic sales in the USA; the remaining 64% of the market represents thus probiotic foods ([@B45]). Therefore, an overall 4.4% probiotic intake among the US population was used to include current probiotic consumption in a scenario analysis. This showed that outcomes were only slightly different from the base case, confirming the robustness of the model.

Discussion {#s5}
==========

We developed a state-transition microsimulation model to quantify the effect of probiotics on RTI-related health and cost outcomes in the USA. The analysis considered the impact of generalized probiotic intake from a health care payer's perspective in primary care, as well as in a broader societal setting by including productivity loss associated with flu-like RTI. The model accurately reproduced the US population structure, the incidence pattern, and the risk factor prevalence over the study period. Two meta-analyses reported clinical benefits of probiotics, one showing a reduction of disease duration and the other both a decrease of disease incidence and duration ([**Table 1**](#T1){ref-type="table"}). While the changes are small at an individual level, when applied to the US population, the health impact is sizable, ranging from an estimated 19,012,000 to 54,491,000 fewer RTI days, 1,393,000 to 2,166,000 averted antibiotic courses, and 3,576,000 to 4,217,000 avoided missed work days, according to the YHEC scenario and the Cochrane scenario, respectively. The Cochrane scenario showed a higher overall impact on public health, due to the fact that it considered both a shorter RTI duration and a reduced RTI incidence. In terms of cost savings, the impact of avoided RTI events, translated to the US population, represented a potential total amount of approximately 1.4 billion USD, of which 370 million USD represents savings for the health care payer.

When cross-validation is performed, the findings of this US analysis were consistent with the previously published French and Canadian assessments ([@B32]; [@B33]). The proportion of avoided RTI days in the population with probiotics versus no probiotics in the models was similar to the results in the current analysis for both the YHEC and Cochrane scenarios. Differences in other outcomes were to be expected due to country-specific characteristics, related to vaccination coverage, prescription patterns, cost inputs, or different conditions in absence from work.

Strengths and Limitations {#s5_1}
-------------------------

In the present analysis, we accurately simulated the US general population structure, vaccination status and prevalence, and the ILI incidence pattern of the studied flu season. The incidence data represented only the proportion of PCP visits due to ILIs, which is known to be relatively low ([@B3]; [@B41]) and likely lead to an underestimation.

One of the base case scenarios only considered the effects of probiotics among the unvaccinated individuals, in line with the results of the Cochrane meta-analysis. The results of the model were therefore conservative, since probiotics can potentially have effects on the vaccinated individuals ([@B46]; [@B47]). Another aspect of probiotic intake not captured in the model concerns the role probiotics may play in the reduction of antibiotic use ([@B29]). The CDC estimates that of the 44% of outpatient antibiotics prescribed to treat patients with respiratory conditions, half are unneeded ([@B10]). Reduced antibiotic use and the associated risk of antibiotic resistance may have considerable public health relevance as well as additional cost consequences ([@B37]).

A limitation of our analysis is that probiotics were considered as a general category and not included in our assessment at the strain level. Different probiotic strains may have different effects on RTIs, but because our evaluation was based on two specific meta-analyses, we effectively included all relevant probiotic strains evaluated in one or more of the clinical trials that were pooled via these meta-analyses. Further, data available for probiotic use in the USA are not segregated based on specific strains. Advances have been made in unraveling the wide array of molecular mechanisms by which probiotic organisms can interact with host cells and on understanding how this might translate into a clinical effect ([@B30]). Certain health benefits depend on core properties that are conserved among different probiotics, while other benefits appear to be more strain specific ([@B24]; [@B42]). An expression of shared efficacy among many different strains may derive from common mechanisms among taxonomic groups that are at a higher order than a strain, such as species or genus. An example of such a shared mechanism is production of short-chain fatty acids. In the case of prevention of RTIs, the mechanism is not known, although it may likely involve probiotic interactions with the immune system. For purposes of this analysis, we consider it sufficient to note that studies included in the meta-analyses, upon which it is based, included interventions from a variety of different *Lactobacillus* and *Bifidobacterium* strains.

As in the previous French and Canadian analyses ([@B32], [@B33]), the cost of probiotics was not included as a factor in our model. Although costs of probiotic foods and dietary supplements do not weigh on the health care payers' resources, their purchase may put an extra burden on the average household expenses. Due to an absence of reliable information and a great variation in products with a wide range of unit prices, it was not possible to evaluate how much this would represent. However, these additional household costs would probably be offset by other expenses, such as costs related to self-medication and purchase of over-the-counter drugs ([@B31]) and costs related to informal care for sick children or the elderly ([@B12]) and associated with missed schooldays ([@B35]; [@B39]).

Conclusion {#s6}
==========

The model demonstrated a positive impact of probiotic consumption on health outcomes in flu-like RTI and the associated patient burden by reducing the number of RTI episodes, the number of days patients spent with RTI symptoms, and the need for antibiotics. Improved patient outcomes translated into considerable cost savings for both the payer and society. These results suggest that recommending daily probiotic consumption may be justified for particular at-risk populations, such as children or individuals with a shared indoor environment, for which this study shows a higher incremental benefit. Such action should be in combination with a cost-effectiveness analysis of implementation to further define the extent to which probiotics contribute to reducing both health care spending and out-of-pocket costs for the management of flu-like infections.
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